1
|
Schorn F, Werthenbach JP, Hoffmann M, Daoud M, Stachelscheid J, Schiffmann LM, Hildebrandt X, Lyu SI, Peltzer N, Quaas A, Vucic D, Silke J, Pasparakis M, Kashkar H. cIAPs control RIPK1 kinase activity-dependent and -independent cell death and tissue inflammation. EMBO J 2023; 42:e113614. [PMID: 37789765 PMCID: PMC10646551 DOI: 10.15252/embj.2023113614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 08/28/2023] [Accepted: 09/07/2023] [Indexed: 10/05/2023] Open
Abstract
Cellular inhibitor of apoptosis proteins (cIAPs) are RING-containing E3 ubiquitin ligases that ubiquitylate receptor-interacting protein kinase 1 (RIPK1) to regulate TNF signalling. Here, we established mice simultaneously expressing enzymatically inactive cIAP1/2 variants, bearing mutations in the RING domains of cIAP1/2 (cIAP1/2 mutant RING, cIAP1/2MutR ). cIap1/2MutR/MutR mice died during embryonic development due to RIPK1-mediated apoptosis. While expression of kinase-inactive RIPK1D138N rescued embryonic development, Ripk1D138N/D138N /cIap1/2MutR/MutR mice developed systemic inflammation and died postweaning. Cells expressing cIAP1/2MutR and RIPK1D138N were still susceptible to TNF-induced apoptosis and necroptosis, implying additional kinase-independent RIPK1 activities in regulating TNF signalling. Although further ablation of Ripk3 did not lead to any phenotypic improvement, Tnfr1 gene knock-out prevented early onset of systemic inflammation and premature mortality, indicating that cIAPs control TNFR1-mediated toxicity independent of RIPK1 and RIPK3. Beyond providing novel molecular insights into TNF-signalling, the mouse model established in this study can serve as a useful tool to further evaluate ongoing therapeutic protocols using inhibitors of TNF, cIAPs and RIPK1.
Collapse
Affiliation(s)
- Fabian Schorn
- Faculty of Medicine and University Hospital of Cologne, Institute for Molecular ImmunologyUniversity of CologneCologneGermany
| | - J Paul Werthenbach
- Faculty of Medicine and University Hospital of Cologne, Institute for Molecular ImmunologyUniversity of CologneCologneGermany
| | - Mattes Hoffmann
- Faculty of Medicine and University Hospital of Cologne, Institute for Molecular ImmunologyUniversity of CologneCologneGermany
| | - Mila Daoud
- Faculty of Medicine and University Hospital of Cologne, Institute for Molecular ImmunologyUniversity of CologneCologneGermany
| | - Johanna Stachelscheid
- Faculty of Medicine and University Hospital of Cologne, Institute for Molecular ImmunologyUniversity of CologneCologneGermany
| | - Lars M Schiffmann
- Faculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Cancer and Transplantation SurgeryUniversity of CologneCologneGermany
| | - Ximena Hildebrandt
- Faculty of Medicine and University Hospital of Cologne, Department of Translational GenomicsUniversity of CologneCologneGermany
| | - Su Ir Lyu
- Faculty of Medicine and University Hospital of Cologne, Institute of Pathology and Center for Integrated Oncology (CIO) Cologne BonnUniversity of CologneCologneGermany
| | - Nieves Peltzer
- Faculty of Medicine and University Hospital of Cologne, Department of Translational GenomicsUniversity of CologneCologneGermany
| | - Alexander Quaas
- Faculty of Medicine and University Hospital of Cologne, Institute of Pathology and Center for Integrated Oncology (CIO) Cologne BonnUniversity of CologneCologneGermany
| | - Domagoj Vucic
- Department of Immunology DiscoveryGenentechSouth San FranciscoCAUSA
| | - John Silke
- The Walter and Eliza Hall Institute for Medical ResearchMelbourneVic.Australia
| | - Manolis Pasparakis
- Institute for GeneticsUniversity of CologneCologneGermany
- Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC)University of CologneCologneGermany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases (CECAD)University of CologneCologneGermany
| | - Hamid Kashkar
- Faculty of Medicine and University Hospital of Cologne, Institute for Molecular ImmunologyUniversity of CologneCologneGermany
- Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC)University of CologneCologneGermany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases (CECAD)University of CologneCologneGermany
| |
Collapse
|
2
|
Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel FCE, Varga JP, Batani J, Bartenhagen C, Schmitz W, Büchel G, Michalke B, Zheng J, Meierjohann S, Girardi E, Espinet E, Flórez AF, dos Santos AF, Aroua N, Cheytan T, Haenlin J, Schlicker L, Xavier da Silva TN, Przybylla A, Zeisberger P, Superti‐Furga G, Eilers M, Conrad M, Fabiano M, Schweizer U, Fischer M, Schulze A, Trumpp A, Friedmann Angeli JP. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med 2023; 15:e18014. [PMID: 37435859 PMCID: PMC10405063 DOI: 10.15252/emmm.202318014] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/23/2023] [Accepted: 06/23/2023] [Indexed: 07/13/2023] Open
Abstract
Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR-activation screens in ferroptosis hypersensitive cells, we identify the selenoprotein P (SELENOP) receptor, LRP8, as a key determinant protecting MYCN-amplified neuroblastoma cells from ferroptosis. Genetic deletion of LRP8 leads to ferroptosis as a result of an insufficient supply of selenocysteine, which is required for the translation of the antiferroptotic selenoprotein GPX4. This dependency is caused by low expression of alternative selenium uptake pathways such as system Xc- . The identification of LRP8 as a specific vulnerability of MYCN-amplified neuroblastoma cells was confirmed in constitutive and inducible LRP8 knockout orthotopic xenografts. These findings disclose a yet-unaccounted mechanism of selective ferroptosis induction that might be explored as a therapeutic strategy for high-risk neuroblastoma and potentially other MYCN-amplified entities.
Collapse
Affiliation(s)
- Hamed Alborzinia
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Zhiyi Chen
- Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational BioimagingUniversity of WürzburgWürzburgGermany
| | - Umut Yildiz
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
- European Molecular Biology Laboratory, Genome Biology UnitHeidelbergGermany
| | - Florencio Porto Freitas
- Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational BioimagingUniversity of WürzburgWürzburgGermany
| | - Felix C E Vogel
- Division of Tumor Metabolism and MicroenvironmentGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Julianna Patricia Varga
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
- European Molecular Biology OrganizationHeidelbergGermany
| | - Jasmin Batani
- Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational BioimagingUniversity of WürzburgWürzburgGermany
| | - Christoph Bartenhagen
- Center for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, University Children's Hospital, Medical FacultyUniversity of CologneCologneGermany
| | - Werner Schmitz
- Department of Biochemistry and Molecular Biology, Theodor Boveri Institute, BiocenterUniversity of WürzburgWürzburgGermany
| | - Gabriele Büchel
- Mildred Scheel Early Career CenterUniversity Hospital WürzburgWürzburgGermany
| | - Bernhard Michalke
- Research Unit Analytical BioGeoChemistryHelmholtz Center München (HMGU)NeuherbergGermany
| | - Jashuo Zheng
- Institute of Metabolism and Cell DeathHelmholtz Zentrum München (HMGU)NeuherbergGermany
| | | | - Enrico Girardi
- CeMM‐Research Center for Molecular Medicine of the Austrian Academy of SciencesViennaAustria
- Solgate GmbHKlosterneuburgAustria
| | - Elisa Espinet
- Anatomy Unit, Department of Pathology and Experimental Therapy, School of MedicineUniversity of Barcelona (UB), L'Hospitalet de LlobregatBarcelonaSpain
- Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell)Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de LlobregatBarcelonaSpain
| | - Andrés F Flórez
- Department of Molecular and Cellular BiologyHarvard UniversityCambridgeMAUSA
| | - Ancely Ferreira dos Santos
- Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational BioimagingUniversity of WürzburgWürzburgGermany
| | - Nesrine Aroua
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Tasneem Cheytan
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Julie Haenlin
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Lisa Schlicker
- Division of Tumor Metabolism and MicroenvironmentGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Thamara N Xavier da Silva
- Division of Tumor Metabolism and MicroenvironmentGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Adriana Przybylla
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Petra Zeisberger
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Giulio Superti‐Furga
- CeMM‐Research Center for Molecular Medicine of the Austrian Academy of SciencesViennaAustria
- Center for Physiology and PharmacologyMedical University of ViennaViennaAustria
| | - Martin Eilers
- Department of Biochemistry and Molecular Biology, Theodor Boveri Institute, BiocenterUniversity of WürzburgWürzburgGermany
| | - Marcus Conrad
- Institute of Metabolism and Cell DeathHelmholtz Zentrum München (HMGU)NeuherbergGermany
| | - Marietta Fabiano
- Institut für Biochemie und Molekularbiologie, Rheinische Friedrich‐Wilhelms‐Universität BonnBonnGermany
| | - Ulrich Schweizer
- Institut für Biochemie und Molekularbiologie, Rheinische Friedrich‐Wilhelms‐Universität BonnBonnGermany
| | - Matthias Fischer
- Center for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, University Children's Hospital, Medical FacultyUniversity of CologneCologneGermany
| | - Almut Schulze
- Division of Tumor Metabolism and MicroenvironmentGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Andreas Trumpp
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‐STEM GmbH)HeidelbergGermany
- Division of Stem Cells and CancerGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - José Pedro Friedmann Angeli
- Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational BioimagingUniversity of WürzburgWürzburgGermany
| |
Collapse
|
3
|
Peschke K, Jakubowsky H, Schäfer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, Öllinger R, Steiger K, Schlitter M, Weichert W, Mayr U, Phillip V, Schlag C, Schmid RM, Braren RF, Kong B, Demir IE, Friess H, Rad R, Saur D, Schneider G, Reichert M. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med 2022; 14:e14876. [PMID: 35119792 PMCID: PMC8988213 DOI: 10.15252/emmm.202114876] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 01/12/2022] [Accepted: 01/13/2022] [Indexed: 02/06/2023] Open
Abstract
Despite the advance and success of precision oncology in gastrointestinal cancers, the frequency of molecular-informed therapy decisions in pancreatic ductal adenocarcinoma (PDAC) is currently neglectable. We present a longitudinal precision oncology platform based on functional model systems, including patient-derived organoids, to identify chemotherapy-induced vulnerabilities. We demonstrate that treatment-induced tumor cell plasticity in vivo distinctly changes responsiveness to targeted therapies, without the presence of a selectable genetic marker, indicating that tumor cell plasticity can be functionalized. By adding a mechanistic layer to precision oncology, adaptive processes of tumors under therapy can be exploited, particularly in highly plastic tumors, such as pancreatic cancer.
Collapse
Affiliation(s)
- Katja Peschke
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Hannah Jakubowsky
- Institute for Translational Cancer Research and Experimental Cancer TherapyTechnical University of MunichMunichGermany
| | - Arlett Schäfer
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Carlo Maurer
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Sebastian Lange
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
- Institute of Molecular Oncology and Functional GenomicsTUM School of MedicineTechnical University of MunichMunichGermany
| | - Felix Orben
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Raquel Bernad
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
- Institute for Translational Cancer Research and Experimental Cancer TherapyTechnical University of MunichMunichGermany
| | - Felix N Harder
- Institute of Diagnostic and Interventional RadiologyTechnical University of MunichMunichGermany
| | - Matthias Eiber
- Department of Nuclear MedicineKlinikum Rechts der IsarTechnical University of MunichMunichGermany
| | - Rupert Öllinger
- Institute of Molecular Oncology and Functional GenomicsTUM School of MedicineTechnical University of MunichMunichGermany
| | - Katja Steiger
- Institute of PathologyTechnical University of MunichMünchenGermany
| | | | - Wilko Weichert
- Institute of PathologyTechnical University of MunichMünchenGermany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)HeidelbergGermany
| | - Ulrich Mayr
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Veit Phillip
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Christoph Schlag
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Roland M Schmid
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| | - Rickmer F Braren
- Institute of Diagnostic and Interventional RadiologyTechnical University of MunichMunichGermany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)HeidelbergGermany
| | - Bo Kong
- Department of SurgeryKlinikum rechts der IsarTechnical University of MunichMunichGermany
- Department of General SurgeryUniversity of UlmUlmGermany
| | - Ihsan Ekin Demir
- Department of SurgeryKlinikum rechts der IsarTechnical University of MunichMunichGermany
| | - Helmut Friess
- Department of SurgeryKlinikum rechts der IsarTechnical University of MunichMunichGermany
| | - Roland Rad
- Institute of Molecular Oncology and Functional GenomicsTUM School of MedicineTechnical University of MunichMunichGermany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)HeidelbergGermany
| | - Dieter Saur
- Institute for Translational Cancer Research and Experimental Cancer TherapyTechnical University of MunichMunichGermany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)HeidelbergGermany
| | - Günter Schneider
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
- Department of General, Visceral and Pediatric SurgeryUniversity Medical Center GöttingenGöttingenGermany
| | - Maximilian Reichert
- Medical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
- German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)HeidelbergGermany
- Center for Protein Assemblies (CPA)Technical University of MunichGarchingGermany
- Translational Pancreatic Cancer Research CenterMedical Clinic and Polyclinic IIKlinikum rechts der IsarTechnical University of MunichMünchenGermany
| |
Collapse
|